## **Core Concept**
The question tests understanding of drugs used in the management of osteoporosis and their mechanisms of action. Osteoporosis treatments can be broadly categorized into anti-resorptive agents, which decrease bone resorption, and bone formative agents, which increase bone formation. A drug that is both anti-resorptive and bone formative would have a dual mechanism of action.

## **Why the Correct Answer is Right**
Teriparatide is a recombinant form of parathyroid hormone (PTH) used in the treatment of osteoporosis. It works by stimulating new bone formation. However, when considering the options provided and common classifications, drugs like **Strontium Ranelate/Strontium Citrate** are known for their dual action: they are anti-resorptive, inhibiting osteoclast activity, and also have a bone formative effect, stimulating osteoblast activity and thereby increasing bone formation.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is not provided, but typically, anti-resorptive drugs like Bisphosphonates (e.g., Alendronate) primarily work by inhibiting osteoclast-mediated bone resorption without a significant bone formative effect.
- **Option B:** Similarly, this option is not specified, but if it represents a typical anti-resorptive agent like Denosumab (a monoclonal antibody against RANKL), it would primarily decrease bone resorption without directly stimulating bone formation.
- **Option D:** Without specifics, if this option represents a drug that is purely bone formative (like Teriparatide) or purely anti-resorptive, it wouldn't fit the dual-action criterion.

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl is that **Strontium Ranelate** has been shown to have a dual effect on bone metabolism, making it a unique option in the treatment of osteoporosis. However, its use has been associated with certain risks, and monitoring is required.

## **Correct Answer:** . Strontium Ranelate.